Literature DB >> 25131933

A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver.

Aras N Mattis1, Guisheng Song, Kelly Hitchner, Roy Y Kim, Andrew Y Lee, Amar D Sharma, Yann Malato, Michael T McManus, Christine C Esau, Erich Koller, Suneil Koliwad, Lee P Lim, Jacquelyn J Maher, Robert L Raffai, Holger Willenbring.   

Abstract

UNLABELLED: Identification of microRNAs (miRNAs) that regulate lipid metabolism is important to advance the understanding and treatment of some of the most common human diseases. In the liver, a few key miRNAs have been reported that regulate lipid metabolism, but since many genes contribute to hepatic lipid metabolism, we hypothesized that other such miRNAs exist. To identify genes repressed by miRNAs in mature hepatocytes in vivo, we injected adult mice carrying floxed Dicer1 alleles with an adenoassociated viral vector expressing Cre recombinase specifically in hepatocytes. By inactivating Dicer in adult quiescent hepatocytes we avoided the hepatocyte injury and regeneration observed in previous mouse models of global miRNA deficiency in hepatocytes. Next, we combined gene and miRNA expression profiling to identify candidate gene/miRNA interactions involved in hepatic lipid metabolism and validated their function in vivo using antisense oligonucleotides. A candidate gene that emerged from our screen was lipoprotein lipase (Lpl), which encodes an enzyme that facilitates cellular uptake of lipids from the circulation. Unlike in energy-dependent cells like myocytes, LPL is normally repressed in adult hepatocytes. We identified miR-29a as the miRNA responsible for repressing LPL in hepatocytes, and found that decreasing hepatic miR-29a levels causes lipids to accumulate in mouse livers.
CONCLUSION: Our screen suggests several new miRNAs are regulators of hepatic lipid metabolism. We show that one of these, miR-29a, contributes to physiological lipid distribution away from the liver and protects hepatocytes from steatosis. Our results, together with miR-29a's known antifibrotic effect, suggest miR-29a is a therapeutic target in fatty liver disease.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25131933      PMCID: PMC4465779          DOI: 10.1002/hep.27379

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

Review 1.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

Review 2.  MicroRNAs: emerging roles in lipid and lipoprotein metabolism.

Authors:  Jennifer Sacco; Khosrow Adeli
Journal:  Curr Opin Lipidol       Date:  2012-06       Impact factor: 4.776

3.  MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia.

Authors:  Kasey C Vickers; Bassem M Shoucri; Michael G Levin; Han Wu; Daniel S Pearson; David Osei-Hwedieh; Francis S Collins; Alan T Remaley; Praveen Sethupathy
Journal:  Hepatology       Date:  2012-07-06       Impact factor: 17.425

4.  Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24.

Authors:  Yuki Oda; Miki Nakajima; Takuya Mohri; Masataka Takamiya; Yasuhiro Aoki; Tatsuki Fukami; Tsuyoshi Yokoi
Journal:  Toxicol Appl Pharmacol       Date:  2012-02-23       Impact factor: 4.219

Review 5.  MicroRNAs in metabolism and metabolic disorders.

Authors:  Veerle Rottiers; Anders M Näär
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-22       Impact factor: 94.444

6.  Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration.

Authors:  Yann Malato; Syed Naqvi; Nina Schürmann; Raymond Ng; Bruce Wang; Joan Zape; Mark A Kay; Dirk Grimm; Holger Willenbring
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

7.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.

Authors:  Wei-Chih Tsai; Sheng-Da Hsu; Chu-Sui Hsu; Tsung-Ching Lai; Shu-Jen Chen; Roger Shen; Yi Huang; Hua-Chien Chen; Chien-Hsin Lee; Ting-Fen Tsai; Ming-Ta Hsu; Jaw-Ching Wu; Hsien-Da Huang; Ming-Shi Shiao; Michael Hsiao; Ann-Ping Tsou
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

8.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

Authors:  Shu-Hao Hsu; Bo Wang; Janaiah Kota; Jianhua Yu; Stefan Costinean; Huban Kutay; Lianbo Yu; Shoumei Bai; Krista La Perle; Raghu R Chivukula; Hsiaoyin Mao; Min Wei; K Reed Clark; Jerry R Mendell; Michael A Caligiuri; Samson T Jacob; Joshua T Mendell; Kalpana Ghoshal
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

Review 9.  Fatty acid regulation of hepatic lipid metabolism.

Authors:  Donald B Jump
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2011-03       Impact factor: 4.294

10.  Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture.

Authors:  F Rinninger; T Kaiser; W A Mann; N Meyer; H Greten; U Beisiegel
Journal:  J Lipid Res       Date:  1998-07       Impact factor: 5.922

View more
  28 in total

1.  Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.

Authors:  Lei Li; Li Che; Kevin M Tharp; Hyo-Min Park; Maria G Pilo; Dan Cao; Antonio Cigliano; Gavinella Latte; Zhong Xu; Silvia Ribback; Frank Dombrowski; Matthias Evert; Gregory J Gores; Andreas Stahl; Diego F Calvisi; Xin Chen
Journal:  Hepatology       Date:  2016-03-25       Impact factor: 17.425

Review 2.  Dysregulated fatty acid metabolism in hepatocellular carcinoma.

Authors:  Mingda Wang; Jun Han; Hao Xing; Han Zhang; Zhenli Li; Lei Liang; Chao Li; Shuyang Dai; Mengchao Wu; Feng Shen; Tian Yang
Journal:  Hepat Oncol       Date:  2017-06-30

Review 3.  The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.

Authors:  Wanyu Deng; Mengji Lu
Journal:  Virol Sin       Date:  2016-12-28       Impact factor: 4.327

4.  Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis.

Authors:  Ming-Xia Liu; Man Gao; Chun-Zhu Li; Cun-Zhi Yu; Hong Yan; Chun Peng; Yu Li; Cheng-Gang Li; Ze-Long Ma; Yang Zhao; Meng-Fan Pu; Ling-Ling Miao; Xin-Ming Qi; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

5.  Dicer-dependent production of microRNA221 in hepatocytes inhibits p27 and is required for liver regeneration in mice.

Authors:  Yuki Oya; Ryota Masuzaki; Daisuke Tsugawa; Kevin C Ray; Yongchao Dou; Seth J Karp
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-02-23       Impact factor: 4.052

6.  A microRNA binding site polymorphism in the 3' UTR region of VEGF-A gene modifies colorectal cancer risk based on ethnicity: a meta-analysis.

Authors:  Sai Sushmitha Kontham; Charles Emmanuel Jebaraj Walter; Zioni Sangeetha Shankaran; Arvind Ramanathan; Nirmala Karuppasamy; Thanka Johnson
Journal:  J Egypt Natl Canc Inst       Date:  2022-04-25

Review 7.  Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?

Authors:  Peter Willeit; Philipp Skroblin; Stefan Kiechl; Carlos Fernández-Hernando; Manuel Mayr
Journal:  Eur Heart J       Date:  2016-04-20       Impact factor: 29.983

8.  Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells.

Authors:  Dan Cao; Xinhua Song; Li Che; Xiaolei Li; Maria G Pilo; Gianpaolo Vidili; Alberto Porcu; Antonio Solinas; Antonio Cigliano; Giovanni M Pes; Silvia Ribback; Frank Dombrowski; Xin Chen; Lei Li; Diego F Calvisi
Journal:  Liver Int       Date:  2016-07-06       Impact factor: 5.828

Review 9.  miRNAs in non-alcoholic fatty liver disease.

Authors:  Zhen He; Cheng Hu; Weiping Jia
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

Review 10.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.